Charles River Laboratories International (CRL) Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRL shares.
View CRL analyst ratings or view top-rated stocks.

11 analysts have issued twelve-month target prices for Charles River Laboratories International's shares. Their CRL share price forecasts range from $203.00 to $275.00. On average, they anticipate the company's stock price to reach $237.36 in the next year. This suggests a possible upside of 18.9% from the stock's current price.
View analysts price targets for CRL or view top-rated stocks among Wall Street analysts.

Charles River Laboratories International's stock was trading at $217.90 at the start of the year. Since then, CRL shares have decreased by 8.4% and is now trading at $199.62.
View the best growth stocks for 2023 here.

Charles River Laboratories International saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,540,000 shares, an increase of 11.6% from the August 15th total of 1,380,000 shares. Based on an average daily trading volume, of 446,500 shares, the short-interest ratio is presently 3.4 days.
View Charles River Laboratories International's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our CRL earnings forecast.

Charles River Laboratories International, Inc. (NYSE:CRL) announced its quarterly earnings data on Wednesday, August, 9th. The medical research company reported $2.69 EPS for the quarter, beating the consensus estimate of $2.63 by $0.06. The medical research company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. Charles River Laboratories International had a trailing twelve-month return on equity of 18.99% and a net margin of 11.58%. The firm's revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the business earned $2.77 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Charles River Laboratories International (NYSE:CRL) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Future Fund Active ETF (FFND), Future Fund Long/Short ETF (FFLS), Horizon Kinetics Inflation Beneficiaries ETF (INFL), Franklin Genomic Advancements ETF (HELX), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

Charles River Laboratories International updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided EPS guidance of $10.30-$10.90 for the period, compared to the consensus earnings per share estimate of $10.37. The company issued revenue guidance of $4.08 billion-$4.16 billion, compared to the consensus revenue estimate of $4.13 billion.

291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Charles River Laboratories International's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.16%), State Street Corp (4.08%), Clearbridge Investments LLC (3.42%), Kayne Anderson Rudnick Investment Management LLC (3.28%), Allspring Global Investments Holdings LLC (2.32%) and Geode Capital Management LLC (2.15%). Insiders that own company stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Shannon M Parisotto, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends.

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRL stock can currently be purchased for approximately $199.62.

Charles River Laboratories International (NYSE:CRL) has a market capitalization of $10.23 billion and generates $3.98 billion in revenue each year. The medical research company earns $486.23 million in net income (profit) each year or $9.43 on an earnings per share basis.

The company employs 21,400 workers across the globe.

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The official website for the company is www.criver.com. The medical research company can be reached via phone at (781) 222-6000, via email at askcharlesriver@crl.com, or via fax at 978-988-5665.